Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Influence of SGLT2 Inhibitor Treatment on Urine Antioxidant Status in Type 2 Diabetic Patients: A Pilot Study
Diana Nabrdalik-Leśniak, Katarzyna Nabrdalik, Katarzyna Sedlaczek, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 20

Showing 20 citing articles:

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 149
Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
Agata Winiarska, Monika Knysak, Katarzyna Nabrdalik, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10822-10822
Open Access | Times Cited: 125
The Role of Oxidative Stress in Kidney Injury
Nejc Piko, Sebastjan Bevc, Radovan Hojs, et al.
Antioxidants (2023) Vol. 12, Iss. 9, pp. 1772-1772
Open Access | Times Cited: 30
Antioxidant Roles of SGLT2 Inhibitors in the Kidney
Carmen Llorens-Cebrià, Mireia Molina-Van den Bosch, Ander Vergara, et al.
Biomolecules (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 29
Semiconducting Polymer Nanoparticles-Manganese Based Chemiluminescent Platform for Determining Total Antioxidant Capacity in Diabetic Mice
Na Wu, Chang Lu, Youjuan Wang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 16, pp. 6603-6611
Closed Access | Times Cited: 18
SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?
Patrick Savage, Lana Dixon, David J. Grieve, et al.
Cardiology in Review (2024)
Open Access | Times Cited: 4
SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway
Xiaochun Zeng, Yuan Tian, Xianming Liang, et al.
Diabetology & Metabolic Syndrome (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 4
BIOMARKERS OF OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES
Rukhsana Sultana, Giovanna Cenini, D. Allan Butterfield
(2025), pp. 437-454
Closed Access
THE ROLE OF OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE (CKD)
Ara Aboolian, Joe Younes, Alejandra Romero, et al.
(2025), pp. 417-436
Closed Access
SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2
Xiang Cai, Huanyi Cao, Meijun Wang, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
A Study to Evaluate the Effect of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors on Oxidative Stress Parameters in Type 2 Diabetes Mellitus Patients
Ankita Sharma, D Aruna, Anne Beatrice
Cureus (2024)
Open Access | Times Cited: 2
Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
Panagiotis Theofilis, Aikaterini Vordoni, Rigas Kalaitzidis
Life (2022) Vol. 12, Iss. 10, pp. 1663-1663
Open Access | Times Cited: 10
Can sodium-glucose cotransporter 2 inhibitors ‘spin the thread of life’?
Giuseppe Maltese, Theocharis Koufakis, Kalliopi Kotsa, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 34, Iss. 1, pp. 1-4
Closed Access | Times Cited: 10
Redox regulation in diabetic kidney disease
Ilse S. Daehn, Ubong S. Ekperikpe, Krisztián Stadler
AJP Renal Physiology (2023) Vol. 325, Iss. 2, pp. F135-F149
Open Access | Times Cited: 6
The influence of SGLT2 inhibitors on oxidative stress in heart failure and chronic kidney disease in patients with type 2 diabetes
Diana Nabrdalik-Leśniak, Katarzyna Nabrdalik, Krzysztof Irlik, et al.
Endokrynologia Polska (2023)
Open Access | Times Cited: 4
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes
Maria Ryaboshapkina, Regina Ye, Yumei Ye, et al.
Cardiovascular Drugs and Therapy (2023)
Closed Access | Times Cited: 4
Prevalence and Clinical Significance of Occult Pulmonary Infection in Elderly Patients with Type 2 Diabetes Mellitus
Jian Hua, Ping Huang, Honghui Liao, et al.
BioMed Research International (2021) Vol. 2021, pp. 1-6
Open Access | Times Cited: 10
Assessment of Insulin Resistance, Oxidative Stress, and Liver Function in Type 2 Diabetic Patients on Dapagliflozin
khalil Amjad Hadid, Fawaz A. Alassaf, Mohammed N. Abed, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Luseogliflozin and caloric intake restriction increase superoxide dismutase 2 expression, promote antioxidative effects, and attenuate aortic endothelial dysfunction in diet‐induced obese mice
Shigeru Kawade, Kazuma Ogiso, Sigfrid Casmir Shayo, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 4, pp. 548-559
Open Access | Times Cited: 2
Sodium-Glucose Cotransporter-2 Inhibitors In Heart Failure
Wojciech Kaźmierski, Jakub Jurek, Paulina Lis, et al.
Prospects in Pharmaceutical Sciences (2024) Vol. 22, Iss. 3, pp. 225-232
Open Access
Page 1

Scroll to top